产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.
特点和优势
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C18H17N3O4S · HCl |
| 分子量 | 407.87 |
| MDL编号 | MFCD19440802 |
| PubChem化学物质编号 | 329825181 |
| NACRES | NA.25 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | pink to purple |
| 溶解性 | DMSO: ≥15 mg/mL |
| 创始人 | Abbott |
| 储存温度 | 2-8℃ |
| SMILES string | Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3 |
| InChI | 1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H |
| InChI key | KWQWWUXRGIIBAS-UHFFFAOYSA-N |
安全信息
| 象形图 | ![]() |
| 警示用语: | Warning |
| 危险声明 | H302 - H315 - H319 - H335 |
| 预防措施声明 | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| 危险分类 | Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| 靶器官 | Respiratory system |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |

Sigma-Aldrich
